Glaxosmithkline Research & Development Ltd

ACTIVE

Unknown Belgian address 0, Unknown, United Kingdomgsk.comSubsidiary

Part of Glaxo Group Ltd.

Clinical Trials

785

783 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

429

54.6%

Phase 3

0.1%

Trial Status Distribution

Active, not recruiting

783

99.8%

Recruiting

0.3%

Clinical Trials

Trials sponsored by this organization (785)

inerixibat Long-term Safety and Tolerability Study (LLSAT)

Phase 1

Active, not recruiting

Oct 2022295 participants

Effect of Mepolizumab in severe bilateral nasal polyps

Phase 1

Active, not recruiting

May 2022414 participants

A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination with Pembrolizumab and 5FU-Platinum Chemotherapy versus Placebo in Combination with Pembrolizumab plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1

Active, not recruiting

May 2022116 participants

Study in dialysis-dependant participants with anemia of chronic kidney disease to assess the efficacy, safety and pharmacokinetics of daprodustat given three-times weekly compared to epoetin alfa

Phase 1

Active, not recruiting

May 2022407 participants

Efficacy Comparison of Dostarlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy in Participants with Metastatic Non squamous Non small Cell Lung Cancer

Phase 1

Active, not recruiting

May 2022240 participants

Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants with Relapsed or Refractory Multiple Myeloma (DREAMM-14)

Phase 1

Active, not recruiting

interventional

Feb 2022180 participants

Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants with Relapsed or Refractory Multiple Myeloma (DREAMM-14)

Phase 1

Active, not recruiting

Feb 2022180 participants

inerixibat Long-term Safety and Tolerability Study (LLSAT)

Phase 1

Active, not recruiting

Nov 2021295 participants

Page 1 of 99

Approvals

No approval data available

News

No news articles found

Back to Organizations